Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Ps Multiple | 1.5x - 1.7x | 1.6x |
| Selected Fwd Ps Multiple | 1.4x - 1.6x | 1.5x |
| Fair Value | €215.54 - €238.23 | €226.89 |
| Upside | -6.3% - 3.6% | -1.4% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| Quest Diagnostics Incorporated | - | NYSE:DGX |
| Cryo-Cell International, Inc. | - | NYSEAM:CCEL |
| Guardant Health, Inc. | - | NasdaqGS:GH |
| OPKO Health, Inc. | - | NasdaqGS:OPK |
| Precipio, Inc. | - | NasdaqCM:PRPO |
| Labcorp Holdings Inc. | - | DB:N6B |
| Select Price / LTM Sales Ratio | ||||||||
| Benchmark Companies | ||||||||
| DGX | CCEL | GH | OPK | PRPO | N6B | |||
| NYSE:DGX | NYSEAM:CCEL | NasdaqGS:GH | NasdaqGS:OPK | NasdaqCM:PRPO | DB:N6B | |||
| Historical Sales Growth | ||||||||
| 5Y CAGR | 5.0% | 0.1% | 28.1% | -4.6% | 42.7% | 2.4% | ||
| 3Y CAGR | -2.9% | 3.5% | 25.5% | -26.2% | 27.9% | -0.3% | ||
| Latest Twelve Months | 12.6% | 1.1% | 28.7% | -7.3% | 27.0% | 8.0% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 12.9% | 0.0% | -95.1% | -15.1% | -90.5% | 9.6% | ||
| Prior Fiscal Year | 9.2% | -30.4% | -85.0% | -21.9% | -38.5% | 3.1% | ||
| Latest Fiscal Year | 8.8% | 1.3% | -59.0% | -7.5% | -23.1% | 5.7% | ||
| Latest Twelve Months | 9.0% | -0.5% | -49.9% | -26.7% | -15.5% | 5.7% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 12.9x | 9.7x | -19.4x | -6.9x | -19.8x | 15.6x | ||
| Price / LTM Sales | 1.9x | 1.1x | 8.8x | 1.6x | 1.1x | 1.7x | ||
| LTM P/E Ratio | 21.6x | -205.5x | -17.7x | -6.1x | -12.9x | 29.4x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/S Ratio | 1.1x | 1.6x | 8.8x | |||||
| Historical LTM P/S Ratio | 1.5x | 1.6x | 1.8x | |||||
| Selected Price / Sales Multiple | 1.5x | 1.6x | 1.7x | |||||
| (x) LTM Sales | 13,484 | 13,484 | 13,484 | |||||
| (=) Equity Value | 20,732 | 21,824 | 22,915 | |||||
| (/) Shares Outstanding | 83.1 | 83.1 | 83.1 | |||||
| Implied Value Range | 249.49 | 262.62 | 275.75 | |||||
| FX Rate: USD/EUR | 1.2 | 1.2 | 1.2 | Market Price | ||||
| Implied Value Range (Trading Cur) | 214.43 | 225.72 | 237.01 | 230.00 | ||||
| Upside / (Downside) | -6.8% | -1.9% | 3.0% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | DGX | CCEL | GH | OPK | PRPO | N6B | |
| Value of Common Equity | 20,445 | 35 | 7,304 | 1,080 | 23 | 22,237 | |
| (/) Shares Outstanding | 111.8 | 8.1 | 124.7 | 793.8 | 1.6 | 83.1 | |
| Implied Stock Price | 182.83 | 4.37 | 58.57 | 1.36 | 14.30 | 267.60 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.16 | |
| Implied Stock Price (Trading Cur) | 182.83 | 4.37 | 58.57 | 1.36 | 14.30 | 230.00 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.16 | |